At the time of writing, Aurinia Pharmaceuticals Inc [AUPH] stock is trading at $11.37, down -0.52%. An important factor to consider is whether the stock is rising or falling in short-term value. The AUPH shares have gain 8.39% over the last week, with a monthly amount glided 27.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer downgraded its rating to Perform on November 04, 2022. Oppenheimer upgraded its rating to a Outperform and decreased its price target to $31 on December 10, 2021. Oppenheimer downgraded its rating to a Perform but $32 remained the price target by the analyst firm on October 28, 2021. H.C. Wainwright reiterated a Buy rating for this stock on January 25, 2021, and upped its price target to $35. In a note dated November 03, 2020, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $34 to $28.
For the past year, the stock price of Aurinia Pharmaceuticals Inc fluctuated between $5.29 and $11.80. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $11.37 at the most recent close of the market. An investor can expect a potential drop of -5.45% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
According to Aurinia Pharmaceuticals Inc [NASDAQ:AUPH], the company’s sales were 260.11M for trailing twelve months, which represents an 22.41% jump. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.17 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] has a current ratio of 5.23. On the other hand, the Quick Ratio is 4.63, and the Cash Ratio is 0.68. Considering the valuation of this stock, the price to sales ratio is 5.75, the price to book ratio is 4.50 and price to earnings (TTM) ratio is 26.59.
Transactions by insiders
Recent insider trading involved TANG KEVIN, Director, that happened on Aug 01 ’25 when 1.0 million shares were purchased. Director, TANG KEVIN completed a deal on Aug 05 ’25 to buy 0.2 million shares. Meanwhile, Director TANG KEVIN bought 100000.0 shares on Aug 04 ’25.
